Evidence map›Paper›PMID 27725639›Full record

ReviewNature reviews. Urology2017

Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations.

Jeffrey J Tosoian, Michael A Gorin, Ashley E Ross, Kenneth J Pienta, Phuoc T Tran, Edward M Schaeffer

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04011410 (Phase 2 Study of Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer), which is not on this map. Cited by 134 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04011410 phase2completednot on this mapstarted 2019, after this paper: background citation

Phase 2 Study of Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer

TypeinterventionalSponsorPatrick HensleyRan2019 to 2024Enrolled20ConditionsProstate Cancer RecurrentArmsHydroxychloroquine Sulfate 200Mg Tab
3 · Its place in the literature

Who cites it

134 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  6. [European journal of nuclear medicine and molecular imaging · 2023
    Trial
  7. Trial
  8. Trial
  9. A Prospective Study onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Trial
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Multimodal therapy for oligometastases after curative esophagectomy for esophageal cancer.Esophagus : official journal of the Japan Esophageal Society · 2025
    Article

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jeffrey J TosoianThe James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Marburg 134, Baltimore, MD 21287, USA.
Michael A GorinThe James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Marburg 134, Baltimore, MD 21287, USA.
Ashley E RossThe James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Marburg 134, Baltimore, MD 21287, USA.
Kenneth J PientaThe James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Marburg 134, Baltimore, MD 21287, USA.
Phuoc T TranDepartment of Radiation Oncology &Molecular Radiation Sciences, Johns Hopkins University School of Medicine, 401 North Broadway, Weinberg Building, Ground Floor Room 1389A, Baltimore, MD 21231, USA.
Edward M SchaefferDepartment of Urology, Northwestern University, 303 East Chicago Avenue, Tarry Building 16-713, Chicago, Illinois 60611, USA.

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Multidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African AncestryU01CA196390 · NCI · JOHNS HOPKINS UNIVERSITY · PI DE MARZO, ANGELO MICHAEL, PIENTA, KENNETH J. · 2015 to 2020
$5.8M
Structure-Functions Studies of Twist1-induced Radioresistance in Lung CancerR01CA166348 · NCI · JOHNS HOPKINS UNIVERSITY · PI TRAN, PHUOC T. · 2013 to 2017
$1.7M
PSMA Directed Imaging of Prostate Cancer Focus on Androgen Receptor DynamicsU01CA183031 · NCI · JOHNS HOPKINS UNIVERSITY · PI DEWEESE, THEODORE L, POMPER, MARTIN G · 2015 to 2017
$1.2M
NCI NIH HHS P30 CA006973NCI NIH HHS R01 CA166348NCI NIH HHS U01 CA183031NCI NIH HHS U01 CA196390
6 · The paper itself

Abstract

The oligometastatic state has been proposed as an intermediate stage of cancer spread between localized disease and widespread metastases. With improvements in diagnostic modalities such as functional imaging, oligometastatic prostate cancer is being diagnosed with greater frequency than ever before. Furthermore, the paradigm for treatment of advanced prostate cancers is shifting toward a more aggressive approach. Many questions surround the understanding of the process and consequences of oligometastasis, meaning that the contemporary literature offers a wide variety of definitions of oligometastatic prostate cancer. Until genomic data exist to provide a biological component to the definition of oligometastatic disease, a clinical diagnosis made on the basis of up to five extrapelvic lesions is reasonable for use. Retrospective studies suggest that interventions such as radical prostatectomy and local or metastasis-directed radiotherapy can be performed in the metastatic setting with minimal risk of toxic effects. These therapies seem to decrease the need for subsequent palliative interventions, but insufficient data are available to draw reliable conclusions regarding their effect on survival. Thus, a protocol for clinicians to manage the patient presenting with oligometastatic prostate cancer would be a useful clinical tool.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsClinical Decision-MakingHumansMaleNeoplasm MetastasisProstatectomyProstatic NeoplasmsRetrospective StudiesTreatment Outcome

Identifiers

PMID27725639
PMCPMC5808411

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.